Aigen Investment Management LP Purchases New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Aigen Investment Management LP purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 7,504 shares of the company’s stock, valued at approximately $415,000.

A number of other institutional investors and hedge funds also recently modified their holdings of TARS. Jennison Associates LLC increased its position in shares of Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after acquiring an additional 698,712 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after purchasing an additional 420,057 shares during the period. Ally Bridge Group NY LLC bought a new position in Tarsus Pharmaceuticals during the third quarter valued at $10,587,000. Ikarian Capital LLC grew its holdings in Tarsus Pharmaceuticals by 28.7% during the third quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after purchasing an additional 230,000 shares during the period. Finally, Vestal Point Capital LP bought a new position in Tarsus Pharmaceuticals during the third quarter valued at $7,565,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $46.47 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The firm has a market capitalization of $1.78 billion, a P/E ratio of -12.20 and a beta of 1.05. The business has a fifty day moving average price of $50.14 and a 200-day moving average price of $43.61.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. As a group, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Barclays cut their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Finally, Jefferies Financial Group raised their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $63.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.